🔴 Zevra Therapeutics is trading 5% down in pre-market amid weaker Nasdaq futures and broader risk-off conditions

Zevra Therapeutics is trading 5.16% down now at $11.39, based on the provided pre-market price context, as weaker Nasdaq futures and broader risk-off conditions weigh on the stock.

• No fresh company-specific overnight catalyst was identified.
• The company is scheduled to present at the Morgan Stanley Global Healthcare Conference on September 14, 2026, at 5:35 p.m. ET.